A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT

BMC Surgery

Volumn 10, Issue , 2010, Pages

  Goralczyk, Armin D ^a   Schnitzbauer, Andreas ^b   Tsui, Tung Y ^c   Ramadori, Giuliano ^a   Lorf, Thomas ^a   Obed, Aiman ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DRUG DERIVATIVE; EVEROLIMUS; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; RAPAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TREATMENT OUTCOME;

EID: 77950688167     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-10-15     Document Type: Article

References (28)

1. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. AS Paramesh S Roayaie Y Doan ME Schwartz S Emre T Fishbein S Florman GE Gondolesi N Krieger S Ames JS Bromberg E Akalin, Clin Transplant 2004 18 94 99 10.1046/j.1399-0012.2003.00132.x 15108777 (Pubitemid 38195551)
2. Chronic renal failure after transplantation of a nonrenal organ. AO Ojo PJ Held FK Port RA Wolfe AB Leichtman EW Young J Arndorfer L Christensen RM Merion, N Engl J Med 2003 349 10 931 940 10.1056/NEJMoa021744 12954741 (Pubitemid 37064766)
3. -2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006 Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation 2007
4. The side-effects of ciclosporine-A and tacrolimus. MJ Mihatsch M Kyo K Morozumi Y Yamaguchi V Nickeleit B Ryffel, Clin Nephrol 1998 49 6 356 363 9696431 (Pubitemid 28271466)
5. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. I Bilbao L Castells L Rojas J Cancino C Dopazo E Castro L Pou R Andino C Margarit, Int Immunopharmacol 2006 6 13-14 1977 1983 10.1016/j.intimp.2006.09.022 17161351 (Pubitemid 44855705)
6. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. TA Gonwa ML Mai LB Melton SR Hays RM Goldstein MF Levy GB Klintmalm, Transplantation 2001 72 12 1934 1939 10.1097/00007890-200112270-00012 11773892
7. Immunosuppressant-induced metabolic toxicities. GM Danovitch, Transplant Rev 2000 14 2 65 81 10.1053/tr.2000.5377
8. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. AJ Olyaei AM de Mattos WM Bennett, Drug Saf 1999 21 6 471 488 10.2165/00002018-199921060-00004 10612271
9. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. HJ Schlitt A Barkmann KH Boker HH Schmidt N Emmanouilidis J Rosenau MJ Bahr G Tusch MP Manns B Nashan J Klempnauer, Lancet 2001 357 9256 587 591 10.1016/S0140-6736(00)04055-1 11558484 (Pubitemid 32179611)
10. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. S Beckebaum VR Cicinnati CG Klein E Brokalaki Z Yu M Malago A Frilling G Gerken CE Broelsch, Transplant Proc 2004 36 9 2671 2674 10.1016/j.transproceed.2004.10.008 15621120
11. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. DJ Reich PA Clavien EE Hodge, Transplantation 2005 80 18 25 10.1097/01.TP.0000165118.00988.D7 16003228
12. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. GP Pageaux L Rostaing Y Calmus C Duvoux C Vanlemmens J Hardgwissen PH Bernard E Barbotte L Vercambre M Bismuth P Puche F Navarro D Larrey, Liver Transpl 2006 12 12 1755 1760 10.1002/lt.20903 17133564
13. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. H Kreis R Oberbauer JM Campistol T Mathew P Daloze FP Schena JT Burke Y Brault M Gioud-Paquet JA Scarola JF Neylan, J Am Soc Nephrol 2004 15 3 809 817 10.1097/01.ASN.0000113248.59077.76 14978184
14. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. JM Neuberger RD Mamelok P Neuhaus J Pirenne D Samuel H Isoniemi L Rostaing A Rimola S Marshall AD Mayer, Am J Transplant 2009 9 2 327 336 10.1111/j.1600-6143.2008.02493.x 19120077
15. Pediatric liver transplantation with daclizumab induction. TG Heffron T Pillen GA Smallwood D Welch B Oakley R Romero, Transplantation 2003 75 12 2040 2043 10.1097/01.TP.0000065740.69296.DA 12829908 (Pubitemid 36793289)
16. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. EM Yoshida PJ Marotta PD Greig NM Kneteman D Marleau M Cantarovich KM Peltekian LB Lilly CH Scudamore VG Bain WJ Wall A Roy RF Balshaw JST Barkun, Liver Transpl 2005 11 9 1064 1072 10.1002/lt.20490 16123958
17. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. CC Lin FR Chuang CH Lee CC Wang YS Chen YW Liu B Jawan CL Chen, Liver Transpl 2005 11 10 1258 1264 10.1002/lt.20520 16184544
18. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. P Neuhaus PA Clavien D Kittur M Salizzoni A Rimola K Abeywickrama E Ortmann L Chodoff M Hall A Korn B Nashan, Liver Transpl 2002 8 2 132 142 10.1053/jlts.2002.30302 11862589
19. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Y Calmus JR Scheele I Gonzalez-Pinto EJ Jaurrieta E Klar GP Pageaux CH Scudamore V Cuervas-Mons HJ Metselaar H Prestele D Girault, Liver Transpl 2002 8 2 123 131 10.1053/jlts.2002.30882 11862588
20. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl] rapamycin in de novo liver transplant recipients. GA Levy D Grant K Paradis J Campestrini T Smith JM Kovarik, Transplantation 2001 71 160 163 10.1097/00007890-200101150- 00028 11211186
21. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. G Levy H Schmidli J Punch E Tuttle-Newhall D Mayer P Neuhaus D Samuel B Nashan J Klempnauer A Langnas Y Calmus X Rogiers M Abecassis R Freeman M Sloof J Roberts L Fischer, Liver Transpl 2006 12 11 1640 1648 10.1002/lt.20707 16598777
22. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. T van Gelder Y Le Meur LM Shaw M Oellerich D DeNofrio C Holt DW Holt B Kaplan D Kuypers B Meiser B Toenshoff RD Mamelok, Ther Drug Monit 2006 28 2 145 154 10.1097/01.ftd.0000199358.80013.bd 16628123 (Pubitemid 44314941)
23. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. EM Yoshida PJ Marotta PD Greig NM Kneteman D Marleau M Cantarovich KM Peltekian LB Lilly CH Scudamore VG Bain WJ Wall A Roy RF Balshaw JST Barkun, Liver Transpl 2005 11 9 1064 1072 10.1002/lt.20490 16123958
24. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. GJ Chang HD Mahanty D Quan CE Freise NL Ascher JP Roberts PG Stock R Hirose, Liver Transpl 2000 6 6 734 740 10.1053/jlts.2000.19023 11084060
25. Cyclosporin versus tacrolimus for liver transplanted patients. EM Haddad VC McAlister E Renouf R Malthaner MS Kjaer LL Gluud, Cochrane Database Syst Rev 2006 4 D005161 17054241
26. Optimal two-stage designs for phase II clinical trials. R Simon, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835
27. SC Chow J Shao H Wang, Sample Size Calculations in Clinical Research Chapman and Hall/CRC 2008
28. Approximate is Better than "Exact" for Interval Estimation of Binomial Proportions. A Agresti B Coull, American Statistician 1998 52 119 26 10.2307/2685469